Erytech Pharma rises on new U.S. patent

Phaxiam Therapeutics SA

30/11/2021 11:15

** French drug developer's U.S.-listed shares  ERYP.O  rise
~42% to $3.40 premarket
    ** Late on Monday, co said it has received U.S. patent
covering methods of treating solid tumors by administering the
enzymes - methioninase and asparaginase  urn:newsml:reuters.com:*:nGNX13jM3F
    ** Says prior treatment with methioninase shown to sensitize
certain solid tumor types, including gastric cancer, to
asparaginase-based treatment - ERYP  
    ** Co's lead cancer drug candidate, eryaspase, consists of
asparaginase encapsulated inside donor-derived red blood cells
    ** Finding demonstrates potential of the approach to weaken
cancer cells, ideally rendering them more susceptible to lower
levels of standard of care chemotherapies - ERYP
    ** Up to Monday's close, stock had fallen ~74% this year  

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))